Multiple Myeloma
Conditions
Keywords
primary systemic amyloidosis
Brief summary
RATIONALE: Collecting and storing samples of blood, urine, tissue and data from patients with amyloid diseases to test in the laboratory may help the study of this disease in the future. PURPOSE: This research study is collecting samples from patients with amyloid diseases
Detailed description
OBJECTIVES: * To establish and maintain a database of clinical material (i.e., blood, urine, and tissue) and information on patients with amyloid diseases. OUTLINE: Blood, urine, tissue, and bone marrow samples are collected during standard laboratory evaluations to maintain a repository of biospecimens in the Gerry Amyloid Research Laboratory, to permit the correlation of clinical results with measured biological events, and for future research studies. Bone marrow RNA samples are examined for immunoglobulin light-chain gene sequences and amino acids by polymerase chain reaction and positional cloning. Blood serum and urine samples are evaluated for amyloid protein stability by high-resolution calorimetry, isothermal-titration calorimetry, and far- and near-UV circular dichroism and fluorescence spectroscopy. Urine samples are also examined for post-translational modifications (e.g., glycosylation, sulfation, and cross-linking) to identify common features unique to amyloid proteins. Tissue samples are analyzed for biochemical and biophysical properties and for post-translational modifications in light chains. Quality of life is assessed by the 36-Item Short Form Survey (SF-36).
Interventions
analyze clonality
analyze polymerase chain reaction
analyze protein
preserve biologic samples
analyze laboratory biomarkers
perform fluorescence spectroscopy on specimens
assess quality of life at each follow-up for life
Sponsors
Study design
Eligibility
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis or suspicion of amyloidosis PATIENT CHARACTERISTICS: * Referred to the Amyloid Treatment and Research Center at Boston University Medical Center PRIOR CONCURRENT THERAPY: * Not specified
Exclusion criteria
None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Establish a repository to promote biochemical research | life of study |
Secondary
| Measure | Time frame |
|---|---|
| Collection of clinical material and information | life of study |
Countries
United States